信达生物IBI3033启动I期临床 适应症为哮喘、特应性皮炎

新浪财经
Yesterday

药物临床试验登记与信息公示平台数据显示,信达生物制药(苏州)有限公司的一项评估IBI3033在健康受试者中安全性、耐受性及药代动力学的随机、双盲、安慰剂对照、单次给药剂量递增研究已启动。临床试验登记号为CTR20255057,首次公示信息日期为2025年12月18日。该药物剂型为注射液(西林瓶),用法用量按照临床方案给药,用药时程为单次给药。本次试验目的为评估中国健康受试者接受IBI3033单次...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10